DOCSLIB.ORG

Known Bioactives Library: Biomol ICCBL - 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Known Bioactives Library: Biomol ICCBL - 2012 Known Bioactives Library: Biomol ICCBL - 2012 ICCB-L ICCB-L Vendor Vendor ID Compound Name Compound description Plate Well 3402 A03 Enzo Life Sciences SL-115 C16 Ceramide Bioactive lipids: Activates PKC zeta 3402 A04 Enzo Life Sciences L-120 C-PAF Bioactive lipids: PAF receptor agonist 3402 A05 Enzo Life Sciences SL-145 C8 Ceramine Bioactive lipids: Ceramide analog. Apoptosis inducer 3402 A06 Enzo Life Sciences PG-047 D12-Prostaglandin J2 Bioactive lipids: Bioactive prostaglandin 3402 A07 Enzo Life Sciences FA-021 (R)-(+)-Methandamide CNS receptor ligands: Cannabinoid CB1 receptor agonist 3402 A08 Enzo Life Sciences FA-009 Dihomo-gamma-linolenic acid Bioactive lipids: Polyunsaturated fatty acid 3402 A09 Enzo Life Sciences DM-200 1α,25-Dihydroxyvitamin D3 Nuclear receptor ligands: Vitamin D receptor agonist 3402 A10 Enzo Life Sciences SL-125 Dihydrosphingosine Bioactive lipids: Apoptosis inducer 3402 A11 Enzo Life Sciences DG-100 1,2-Didecanoyl-glycerol (10:0) Bioactive lipids: Activates PKC 3402 A12 Enzo Life Sciences GR-207 Diidolylmethane Nuclear receptor ligands: AHR agonist 3402 A13 Enzo Life Sciences DG-112 1,2-Dioctanoyl-SN-glycerol Bioactive lipids: Activates PKC 3402 A14 Enzo Life Sciences SL-205 DL-Dihydrosphingosine Lipid biosynthesis: Sphingosine kinase inhibitor 3402 A15 Enzo Life Sciences DG-115 1,2-Dioleoyl-glycerol (18:1) Bioactive lipids: Activates PKC 3402 A16 Enzo Life Sciences SL-210 DL-PDMP Lipid biosynthesis: Glucosylceramide synthase inhibitor 3402 A17 Enzo Life Sciences EE-11 (±)11(12)-Epoxyeicosatrienoic acid Bioactive lipids: Bioactive arachidonic acid metabolite 3402 A18 Enzo Life Sciences SL-215 DL-PPMP Lipid biosynthesis: Glucosylceramide synthase inhibitor 3402 A19 Enzo Life Sciences H-112 12(R)-HETE Bioactive lipids: Bioactive arachidonic acid metabolite 3402 A20 Enzo Life Sciences FA-002 Docosahexaenoic acid(22:6 n-3) Bioactive lipids: Polyunsaturated fatty acid 3402 A21 Enzo Life Sciences H-012 12(S)-HETE Bioactive lipids: Bioactive arachidonic acid metabolite 3402 A22 Enzo Life Sciences FA-012 Docosapentaenoic acid Bioactive lipids: Polyunsaturated fatty acid 3402 B03 Enzo Life Sciences AC-104 Bepridil·HCl Ion channel ligands: Calcium channels 3402 B04 Enzo Life Sciences GR-313 Lycorine Inhibitors: inhibits TNFalpha production 3402 B05 Enzo Life Sciences CA-415 Cyclopiazonic acid Ion channel ligands: Intracellular calcium 3402 B06 Enzo Life Sciences GR-316 10-hydroxycamptothecin Inhibitors: topoisomerase 1 inhibitor 3402 B07 Enzo Life Sciences AC-100 Dantrolene Ion channel ligands: Intracellular calcium 3402 B08 Enzo Life Sciences GR-308 Beta-lapachone Inhibitors: topoisomerase 1 inhibitor 3402 B09 Enzo Life Sciences KC-115 Diazoxide Ion channel ligands: Potassium channels 3402 B10 Enzo Life Sciences T-113 Parthenolide Inhibitors: IkappaB kinase inhibitor 3402 B11 Enzo Life Sciences CA-204 Dichlorobenzamil·HCl Ion channel ligands: Calcium channels 3402 B12 Enzo Life Sciences PI-102 MG-132 Protease inhibitors: Proteasome inhibitor 3402 B13 Enzo Life Sciences CA-205 Diltiazem·HCl Ion channel ligands: Calcium channels 3402 B14 Enzo Life Sciences EI-352 QNZ Inhibitors: NFkappaB inhibitor 3402 B15 Enzo Life Sciences KC-158 E-4031 Ion channel ligands: Potassium channels 3402 B16 Enzo Life Sciences GR-211 bezafibrate Nuclear receptor ligands: PPAR alpha agonist 3402 B17 Enzo Life Sciences CM-102 Fipronil Ion channel ligands: Misc. channels 3402 B18 Enzo Life Sciences IM-100 Cycloheximide-N-ethylethanoate Inhibitors: FKBP12 inhibitor 3402 B19 Enzo Life Sciences AC-130 Flecainide acetate Ion channel ligands: Sodium channels 3402 B20 Enzo Life Sciences A-165 Ascomycin (FK-520) Inhibitors: binds to FKBP inhibits calcineurin 3402 B21 Enzo Life Sciences AC-123 Flufenamic acid Ion channel ligands: Potassium channels 3402 B22 Enzo Life Sciences FR-100 U-74389G Inhibitors: superoxide/free-radical inhibitor 3402 C03 Enzo Life Sciences HP-012 12(S)-HPETE Bioactive lipids: Fatty acid hydroperoxide 3402 C04 Enzo Life Sciences FA-010 Docosatrienoic acid (22:3 n-3) Bioactive lipids: Polyunsaturated fatty acid 3402 C05 Enzo Life Sciences G-234 12-Methoxydodecanoic acid Bioactive lipids: Myristic acid analog 3402 C06 Enzo Life Sciences FA-024 Eicosa-5,8-dienoic acid (20:2 n-12) Bioactive lipids: Polyunsaturated fatty acid 3402 C07 Enzo Life Sciences HO-013 13(S)-HODE Bioactive lipids: Bioactive linoleic acid metabolite 3402 C08 Enzo Life Sciences FA-007 Eicosadienoic acid (20:2 n-6) Bioactive lipids: Polyunsaturated fatty acid 3402 C09 Enzo Life Sciences HP-013 13(S)-HPODE Bioactive lipids: Fatty acid hydroperoxide 3402 C10 Enzo Life Sciences FA-001 Eicosapentaenoic acid (20:5 n-3) Bioactive lipids: Polyunsaturated fatty acid 3402 C11 Enzo Life Sciences PG-048 13,14-Dihydro-PGE1 Bioactive lipids: Bioactive prostaglandin 3402 C12 Enzo Life Sciences FA-008 Eicosatrienoic acid (20:3 n-3) Bioactive lipids: Polyunsaturated fatty acid 3402 C13 Enzo Life Sciences GR-102 13-cis retinoic acid Nuclear receptor ligands: Retinoid receptor ligand 3402 C14 Enzo Life Sciences L-110 Enantio-PAF C16 Bioactive lipids: Negative control for PAF 13-Keto-octadeca-9Z,11E-dienoic 3402 C15 Enzo Life Sciences KO-013 Bioactive lipids: Bioactive linoleic acid metabolite acid 3402 C16 Enzo Life Sciences G-222 Farnesylthioacetic acid Bioactive lipids: Carboxymethylation inhibitor (±)14,15-Epoxyeicosa-5Z,8Z,11Z- 3402 C17 Enzo Life Sciences EE-14 Bioactive lipids: Bioactive arachidonic acid metabolite trienoic acid 3402 C18 Enzo Life Sciences RA-105 Fluprostenol Bioactive lipids: Prostaglandin FP receptor agonist 3402 C19 Enzo Life Sciences H-015 15(S)-HETE Bioactive lipids: Bioactive arachidonic acid metabolite 3402 C20 Enzo Life Sciences FA-006 Gamma-linolenic acid (18:3 n-6) Bioactive lipids: Polyunsaturated fatty acid 3402 C21 Enzo Life Sciences HP-015 15(S)-HPETE Bioactive lipids: Fatty acid hydroperoxide 3402 C22 Enzo Life Sciences LE-009 Leukotoxin A (9,10-EODE) Bioactive lipids: Bioactive linoleic acid metabolite 3402 D03 Enzo Life Sciences CA-225 Flunarizine·2HCl Ion channel ligands: Calcium channels 3402 D04 Enzo Life Sciences EI-207 Ebselen Inhibitors: glutathione peroxidase mimetic 3402 D05 Enzo Life Sciences AC-116 Fluspirilene Ion channel ligands: Potassium channels 3402 D06 Enzo Life Sciences CN-266 TRIM Inhibitors: bNOS/iNOS inhibitor 3402 D07 Enzo Life Sciences CA-245 FPL-64176 Ion channel ligands: Calcium channels 3402 D08 Enzo Life Sciences PD-195 Zardaverine Inhibitors: phosphodiesterase (PDE1/2) inhibitor 3402 D09 Enzo Life Sciences CA-422 6-Gingerol Ion channel ligands: Intracellular calcium 3402 D10 Enzo Life Sciences PD-190 Zaprinast Inhibitors: phosphodiesterase (PDE1) inhibitor 3402 D11 Enzo Life Sciences AC-120 Glipizide Ion channel ligands: Potassium channels 3402 D12 Enzo Life Sciences PD-185 Vinpocetine Inhibitors: phosphodiesterase (PDE1) inhibitor 3402 D13 Enzo Life Sciences KC-120 Glyburide Ion channel ligands: Potassium channels 3402 D14 Enzo Life Sciences PD-180 Trequinsin Inhibitors: phosphodiesterase (PDE3) inhibitor 3402 D15 Enzo Life Sciences NA-135 Grayanotoxin III Ion channel ligands: Sodium channels 3402 D16 Enzo Life Sciences PD-179 Siguazodan Inhibitors: phosphodiesterase (PDE3) inhibitor 3402 D17 Enzo Life Sciences CM-101 R(+)-IAA-94 Ion channel ligands: Misc. channels 3402 D18 Enzo Life Sciences PD-175 Rolipram Inhibitors: phosphodiesterase (PDE4 ) inhibitor 3402 D19 Enzo Life Sciences CA-207 L-cis-Diltiazem·HCl Ion channel ligands: Calcium channels Biomol ICCBL - 2012 Page 1 of 6 Created 9/2015 ICCB-L ICCB-L Vendor Vendor ID Compound Name Compound description Plate Well 3402 D20 Enzo Life Sciences EI-117 Ro 20-1724 Inhibitors: phosphodiesterase (PDE4 ) inhibitor 3402 D21 Enzo Life Sciences AC-128 Lidocaine·HCl·H2O Ion channel ligands: Sodium channels 3402 D22 Enzo Life Sciences PD-155 MY-5445 Inhibitors: phosphodiesterase (PDE5) inhibitor 3402 E03 Enzo Life Sciences PG-050 15-deoxy-Prostaglandin J2 Bioactive lipids: Bioactive prostaglandin 3402 E04 Enzo Life Sciences LE-012 Leukotoxin B (12,13-EODE) Bioactive lipids: Bioactive linoleic acid metabolite 3402 E05 Enzo Life Sciences K-015 15-Ketoicosatetraenoic acid Bioactive lipids: Bioactive arachidonic acid metabolite 3402 E06 Enzo Life Sciences LB-004 Leukotriene B4 Bioactive lipids: Leukotriene B4 receptor agonist 3402 E07 Enzo Life Sciences PG-021 16,16-Dimethyl-prostaglandin E2 Bioactive lipids: Prostaglandin EP receptor agonist 3402 E08 Enzo Life Sciences LC-004 Leukotriene C4 Bioactive lipids: CysLT receptor agonist 3402 E09 Enzo Life Sciences EI-103 17-Octadecynoic acid Lipid biosynthesis: Inhibits fatty acid omega oxidation 3402 E10 Enzo Life Sciences LD-004 Leukotriene D4 Bioactive lipids: CysLT receptor agonist 3402 E11 Enzo Life Sciences PG-042 17-Phenyl-trinor-prostaglandin E2 Bioactive lipids: Prostaglandin EP1 receptor agonist 3402 E12 Enzo Life Sciences LE-004 Leukotriene E4 Bioactive lipids: CysLT1 receptor agonist 3402 E13 Enzo Life Sciences L-134 1-Acyl-PAF Bioactive lipids: PAF agonist 3402 E14 Enzo Life Sciences FA-023 Linoleamide Endocannabinoids: Bioactive linoleic acid metabolite 1-Hexadecyl-2-arachidonoyl- 3402 E15 Enzo Life Sciences DG-140 Bioactive lipids: DAG analog glycerol 3402 E16 Enzo Life Sciences FA-014 Linoleic acid Bioactive lipids: Polyunsaturated fatty acid 3402 E17 Enzo Life Sciences L-106 1-Hexadecyl-2-methylglycero-3 PC Bioactive lipids: PAF receptor agonist 3402 E18 Enzo Life Sciences FA-005 Linolenic acid (18:3 n-3) Bioactive lipids: Polyunsaturated fatty acid 3402 E19 Enzo Life Sciences EI-150 1-Hexadecyl-2-O-acetyl-glycerol
Load more

Recommended publications
  • Biomol Average and SD Table S1.Xlsx
    Compound GliNS1 G179NS G166NS average, n=5 STD average, n=3 STD average, n=3 STD INTRACELLULAR CALCIUM Antibiotic A-23187 0.00 0.00 0.10 0.07 0.15 0.14 INTRACELLULAR CALCIUM Ryanodine 1.04 0.14 1.03 0.03 1.03 0.03 INTRACELLULAR CALCIUM Cyclopiazonic acid 1.01 0.06 0.88 0.05 0.92 0.06 INTRACELLULAR CALCIUM Gingerol 1.00 0.06 0.91 0.01 1.01 0.06 INTRACELLULAR CALCIUM Thapsigargin 0.00 0.01 0.00 0.00 0.10 0.12 INTRACELLULAR CALCIUM TMB-8 0.89 0.07 0.91 0.05 0.94 0.03 INTRACELLULAR CALCIUM Dantrolene 0.91 0.08 0.98 0.05 0.94 0.01 CALCIUM CHANNELS Amiloride 1.01 0.07 1.01 0.04 1.03 0.05 CALCIUM CHANNELS Benzamil 0.83 0.08 0.83 0.12 0.96 0.04 CALCIUM CHANNELS BAY K-8644 0.93 0.13 0.93 0.09 1.07 0.14 CALCIUM CHANNELS Diltiazem 0.96 0.07 0.99 0.12 0.94 0.14 CALCIUM CHANNELS L-cis-Diltiazem 0.91 0.17 1.01 0.12 0.95 0.12 CALCIUM CHANNELS Flunarizine 0.85 0.08 1.00 0.06 0.85 0.05 CALCIUM CHANNELS FPL-64176 0.99 0.11 0.95 0.07 1.05 0.05 CALCIUM CHANNELS Nifedipine 1.06 0.17 0.95 0.12 1.03 0.09 CALCIUM CHANNELS Nimodipine 1.05 0.06 0.95 0.03 1.06 0.17 CALCIUM CHANNELS Nitrendipine 0.99 0.07 0.96 0.10 1.04 0.09 CALCIUM CHANNELS SDZ-202791 R(-) 1.01 0.08 0.92 0.06 1.01 0.08 CALCIUM CHANNELS SKF-96365 0.73 0.05 0.70 0.11 0.69 0.04 CALCIUM CHANNELS Tetrandrine 0.47 0.07 0.76 0.16 0.87 0.20 CALCIUM CHANNELS Verapamil 1.01 0.02 0.89 0.07 1.06 0.20 CALCIUM CHANNELS Methoxy Verapamil 0.93 0.14 0.96 0.07 0.93 0.13 CALCIUM CHANNELS Bepridil 0.70 0.16 0.92 0.15 0.84 0.14 CALCIUM CHANNELS Amiodarone 0.32 0.12 0.58 0.07 0.48 0.23 CALCIUM CHANNELS YS035 1.00 0.16
    [Show full text]
  • Central Valley Toxicology Drug List
    Chloroform ~F~ Lithium ~A~ Chlorpheniramine Loratadine Famotidine Acebutolol Chlorpromazine Lorazepam Fenoprofen Acetaminophen Cimetidine Loxapine Fentanyl Acetone Citalopram LSD (Lysergide) Fexofenadine 6-mono- Clomipramine acetylmorphine Flecainide ~M~ Clonazepam a-Hydroxyalprazolam Fluconazole Maprotiline Clonidine a-Hydroxytriazolam Flunitrazepam MDA Clorazepate Albuterol Fluoxetine MDMA Clozapine Alprazolam Fluphenazine Medazepam Cocaethylene Amantadine Flurazepam Meperidine Cocaine 7-Aminoflunitrazepam Fluvoxamine Mephobarbital Codeine Amiodarone Fosinopril Meprobamate Conine Amitriptyline Furosemide Mesoridazine Cotinine Amlodipine Methadone Cyanide ~G~ Amobarbital Methanol Cyclobenzaprine Gabapentin Amoxapine d-Methamphetamine Cyclosporine GHB d-Amphetamine l-Methamphetamine Glutethamide l-Amphetamine ~D~ Methapyrilene Guaifenesin Aprobarbital Demoxepam Methaqualone Atenolol Desalkylfurazepam ~H~ Methocarbamol Atropine Desipramine Halazepam Methylphenidate ~B~ Desmethyldoxepin Haloperidol Methyprylon Dextromethoraphan Heroin Metoclopramide Baclofen Diazepam Hexobarbital Metoprolol Barbital Digoxin Hydrocodone Mexiletine Benzoylecgonine Dihydrocodein Hydromorphone Midazolam Benzphetamine Dihydrokevain Hydroxychloroquine Mirtazapine Benztropine Diltiazem Hydroxyzine Morphine (Total/Free) Brodificoum Dimenhydrinate Bromazepam ~N~ Diphenhydramine ~I~ Bupivacaine Nafcillin Disopyramide Ibuprofen Buprenorphine Naloxone Doxapram Imipramine Bupropion Naltrexone Doxazosin Indomethacin Buspirone NAPA Doxepin Isoniazid Butabarbital Naproxen
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Kava - the Unfolding Story: Report on a Work-In-Progress
    Article Kava - the unfolding story: Report on a work-in-progress. Denham, Alison, McIntyre, Michael and Whitehouse, Jule Available at http://clok.uclan.ac.uk/9455/ Denham, Alison, McIntyre, Michael and Whitehouse, Jule Kava - the unfolding story: Report on a work-in-progress. Journal of Alternative and Complementary Medicine, 8 (3). pp. 237-263. It is advisable to refer to the publisher’s version if you intend to cite from the work. For more information about UCLan’s research in this area go to http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>. For information about Research generally at UCLan please go to http://www.uclan.ac.uk/research/ All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the policies page. CLoK Central Lancashire online Knowledge www.clok.uclan.ac.uk THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE Volume 8, Number 3, 2002, pp. 237–263 © Mary Ann Liebert, Inc. SPECIAL REPORT Kava—the Unfolding Story: Report on a Work-in-Progress ALISON DENHAM, B.A. (Soc.), M.N.I.M.H., 1 MICHAEL McINTYRE, M.A., F.N.I.M.H., F.R.C.H.M., M.B.Ac.C., 2 and JULIE WHITEHOUSE, Ph.D., M.N.I.M.H. 3 ABSTRACT This paper, originated as a submission (now updated) to the U.K. Medicines Control Agency and Committee of Safety of Medicines (CSM) on January 11, 2002, in response to a report circu- lated by the German Federal Institute for Drugs and Medical Products (German initials are BfArM), a compilation of which is summarized in Appendix 2.
    [Show full text]
  • Letters to the Editor
    Letters to the Editor Internet Pharmacy Prescription complete the medication database. Of course, patients can abuse and Phentermine Overdose any medications, so collaboration between pharmacies and physicians is essential to minimize this risk. Sir: The Internet is now widely used by patients for both Dr. Takeshita reports no financial or other relationship relevant to the health information and prescription services. Yet, a MEDLINE subject matter of this letter. search in January 2002 using the phrase “Internet pharmacy” showed a total of 99 articles; nearly all were geared toward REFERENCES health care management or the general public. There are only a few published reports of bad outcome resulting from medical 1 1. Crocco AG, Villasis-Keever M, Jadad AR. Analysis of cases of information obtained from the Internet. The U.S. Food and harm associated with use of health information on the Internet. Drug Administration noted 326 Internet sites selling pharma- JAMA 2002;287:2867–2871 ceutical products.2 The exact numbers are difficult to quantify 2. Henney JE. Cyberpharmacies and the role of the US Food and Drug as Web sites are constantly changing. I report a case of overdose Administration. J Med Internet Res 2001;3:E3 with phentermine that was obtained through an Internet 3. Gardin JM, Schumacher D, Constantine G, et al. Valvular abnormali- pharmacy. ties and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000;283:1703–1709 4. Koury E, Stone CK, Stapczynski JS, et al. Sympathetic overactivity Case report. Ms. A, a 20-year-old woman with a prior from fenfluramine-phentermine overdose.
    [Show full text]
  • Please Check Desired Specimen Type & Drugs/Drug Classes for Testing
    PATIENT INFORMATION PRACTICE INFORMATION ____________________________________ _____________________________________ _______ ________________________ __________________ Last Name First Name MI Facility/Group Referring Physician ________/________/________ Social Security: _________-_________-________ ☐ Male ☐ Female ___________________________________________ Date of Birth Address NPI Provider Nr. __________________________________________________________________ Address DIAGNOSTIC CODES (ICD-10 codes): _____________________________ ☐ Self-Pay (attach Information) ☐ Commercial Insurance (attach copy) ☐ W/C (Date of Injury): ____________ ☐ Medicare (attach copy of Insurance) I certify that I have voluntarily provided a fresh unadulterated urine/dried blood/oral fluid specimen for analytical testing. The information provided on this form and on the label affixed to the specimen is accurate. I authorize lab to release the results of this testing to the ordering physician. I also authorize lab to bill my insurance provider and to receive payment of benefits for the tests ordered by my physician. I further authorize lab and the ordering physician to release to my insurance provider any medical information necessary to process this claim. I acknowledge that lab may be an out-of-network facility with my insurance provider. Patient Signature (or Legal Guardian): ___________________________________________________________________________ Date: _______________ TEST PANELS (please check desired specimen type & drugs/drug classes for testing): ☐ URINE
    [Show full text]
  • Kava Kava Extract Is Available from Ashland Chemical Co., Mini Star International, Inc., and QBI (Quality Botanical Ingredients, Inc.)
    SUMMARY OF DATA FOR CHEMICAL SELECTION Kava Kava 9000-38-8; 84696-40-2 November 1998 TABLE OF CONTENTS Basis for Nomination Chemical Identification Production Information Use Pattern Human Exposure Regulatory Status Evidence for Possible Carcinogenic Activity Human Data Animal Data Metabolism Other Biological Effects Structure-Activity Relationships References BASIS OF NOMINATION TO THE CSWG Kava kava is brought to the attention of the CSWG because it is a rapidly growing, highly used dietary supplement introduced into the mainstream U.S. market relatively recently. Through this use, millions of consumers using antianxiety preparations are potentially exposed to kava kava. A traditional beverage of various Pacific Basin countries, kava clearly has psychoactive properties. The effects of its long-term consumption have not been documented adequately; preliminary studies suggest possibly serious organ system effects. The potential carcinogenicity of kava and its principal constituents are unknown. INPUT FROM GOVERNMENT AGENCIES/INDUSTRY The U.S. Pharmacopeia is in the process of reviewing kava kava. No decision on preparation of a monograph has been made. SELECTION STATUS ACTION BY CSWG: 12/14/98 Studies requested: - Toxicological evaluation, to include studies of reproductive toxicity and neurotoxicity - Genotoxicity Priority: High Rationale/Remarks: - Significant human exposure - Leading dietary supplement with rapidly growing use - Concern that kava has been promoted as a substitute for ritilin in children - Test extract standardized to 30 percent kavalactones - NCI is conducting studies in Salmonella typhimurium CHEMICAL IDENTIFICATION CAS Registry Number: 9000-38-8 Kava-kava resin (8CI) Chemical Abstract Service Name: 84696-40-2 CAS Registry Number: Pepper (Piper), P. methysticum, ext. Chemical Abstract Service Name: Extract of kava; kava extract; Piper Synonyms and Trade Names: methisticum extract Description: The tropical shrub Piper methysticum is widely cultivated in the South Pacific.
    [Show full text]
  • Kavain, the Major Constituent of the Anxiolytic Kava
    RESEARCH ARTICLE Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism Han Chow Chua1, Emilie T. H. Christensen1,2, Kirsten Hoestgaard-Jensen2, Leonny Y. Hartiadi1, Iqbal Ramzan1, Anders A. Jensen2, Nathan L. Absalom1, Mary Chebib1* 1 Faculty of Pharmacy, The University of Sydney, Sydney, New South Wales, Australia, 2 Department of a11111 Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark * [email protected] Abstract OPEN ACCESS Extracts of the pepper plant kava (Piper methysticum) are effective in alleviating anxiety in Citation: Chua HC, Christensen ETH, Hoestgaard- Jensen K, Hartiadi LY, Ramzan I, Jensen AA, et al. clinical trials. Despite the long-standing therapeutic interest in kava, the molecular target(s) (2016) Kavain, the Major Constituent of the Anxiolytic of the pharmacologically active constituents, kavalactones have not been established. γ- Kava Extract, Potentiates GABAA Receptors: Aminobutyric acid type A receptors (GABAARs) are assumed to be the in vivo molecular tar- Functional Characteristics and Molecular Mechanism. PLoS ONE 11(6): e0157700. doi:10.1371/journal. get of kavalactones based on data from binding assays, but evidence in support of a direct pone.0157700 interaction between kavalactones and GABAARs is scarce and equivocal. In this study, we Editor: Steven Barnes, Dalhousie University, characterised the functional properties of the major anxiolytic kavalactone, kavain at human CANADA recombinant α1β2, β2γ2L, αxβ2γ2L (x = 1, 2, 3 and 5), α1βxγ2L (x = 1, 2 and 3) and α4β2δ Received: March 24, 2016 GABAARs expressed in Xenopus oocytes using the two-electrode voltage clamp technique.
    [Show full text]
  • Un Novedoso Enfoque Para El Diseño De Fármacos Antimicrobianos Asistido Por Computadora
    TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño de Fármacos Antimicrobianos Asistido por Computadora Autora: Yasnay Valdés Rodríguez. Tutores: Prof. Dr. Yovani Marrero Ponce. Prof. MSc. Ricardo Medina Marrero. 2005-2006 La ignorancia afirma o niega rotundamente; la ciencia duda… Voltaire (1694-1778) Quiero dedicar este trabajo a todas aquellas personas que me aprecian y desean lo mejor para mi, especialmente a mis padres. A mi padre Dedico este trabajo con mucho amor, por hacerme comprender que siempre se puede llegar mas lejos, y que no hay nada imposible, solamente hay que luchar... A mi madre Por su infinita bondad, por su sacrificio inigualable. A mis familiares Por todo su apoyo y ayuda que me han mostrado incondicionalmente. A mi hermano Por ser mi fuente de inspiración. A la humanidad “...porque si supiera que el mundo se acaba mañana, yo, hoy todavía, plantaría un árbol” Quiero agradecer a todas aquellas personas que me han ayudado a realizar este sueño: A mis padres por todo el sacrificio realizado, y aún parecerles poco, los amo mucho. A mi madre por estar siempre a mi lado en los buenos y malos momentos ayudándome a levantarme en cualquier recaída. A mi padre por guiarme en la vida y brindarme sus consejos siempre útiles, por darme fuerza y vitalidad. A mi mayor tesoro, mi hermano, que me alumbra de esperanza día a día. A mis tías y primos que me ayudaron mucho, aún estando lejos. A mi novio que me apoyo en todas mis decisiones y con paciencia supo ayudarme. A mis tutores y cotutores que siempre me dieron la mano; especialmente a Yovani por su paciencia, a quien debo gran parte de mi formación como profesional por sus exigencias.
    [Show full text]
  • Big Conductance Calcium-Activated Potassium Channel Openers Control Spasticity Without Sedation
    British Journal of British Journal of Pharmacology (2017) 174 2662–2681 2662 BJP Pharmacology RESEARCH PAPER Big conductance calcium-activated potassium channel openers control spasticity without sedation Correspondence Professor David Baker, Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark Street, Whitechapel, London E1 4AT, UK. E-mail: [email protected] Received 5 January 2017; Revised 27 April 2017; Accepted 17 May 2017 David Baker1,2,* ,GarethPryce1,2,*, Cristina Visintin2,3,SofiaSisay1, Alexander I Bondarenko4,5, WSVanessaHo6, Samuel J Jackson1, Thomas E Williams1, Sarah Al-Izki1, Ioanna Sevastou3, Masahiro Okuyama3, Wolfgang F Graier4, Lesley A Stevenson6,CarolynTanner7,RuthRoss7, Roger G Pertwee7, Christopher M Henstridge8,AndrewJIrving8, Jesse Schulman9,KeithPowell9,MarkDBaker1, Gavin Giovannoni1,2 and David L Selwood3,* 1Neuroimmunology Unit, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK, 2Department of Neuroinflammation, UCL Institute of Neurology, University College London, London, UK, 3Department of Medicinal Chemistry, UCL Wolfson Institute for Biomedical Research, University College London, London, UK, 4Institute of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria, 5A.A. Bogomoletz Institute of Physiology, Kiev, Ukraine, 6Vascular Biology Research Centre. St. George’s, University of London, London, UK, 7Department of Biomedical Sciences,
    [Show full text]
  • Functional Analysis of Penicillium Paxilli Genes Required for Biosynthesis of Paxilline
    Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author. Functional analysis of Penicillium paxilli genes required for biosynthesis of paxilline This thesis is presented in partial fulfilment of the requirements for the degree of Doctor of Philosophy (PhD) In Biochemistry at Massey University, Palmerston North, New Zealand Sanjay Saikia 2006 ABSTRACT Paxilline belongs to a large, structurally and functionally diverse group of indole-diterpenes and is synthesised by the filamentous fungus Penicillium paxilli. A gene cluster for paxilline biosynthesis in P. paxilli has been identified and characterised. However, none of the steps proposed in the biosynthesis of paxilline or paxilline-like indole-diterpenes have been validated . In some diterpene-producing fi lamentous fungi, including P. paxilli, two distinct copies of geranylgeranyl diphosphate (GGPP) synthase, that catalyses the committed step in diterpene biosynthesis, have been identified . However, the biological significance of the presence of two distinct GGPP synthases is not known. In this study, biochemical analysis of the paxilline gene products in P. paxilli and subcellular localisation of the two P. paxilli GGPP synthases, Ggs1 and PaxG, were carried out. Transfer of constructs containing different combinations of pax genes into a pax cluster negative deletion derivative of P. paxilli identified four Pax proteins that are required for the biosynthesis of a paxilline intermediate, paspaline. These proteins are PaxG, a GGPP synthase, PaxM, a FAD-dependent monooxygenase, PaxB, a putative membrane protein, and PaxC, a prenyltransferase.
    [Show full text]